Placeholder Banner

What Will it Take to Bring New Pain Therapies to the Market? A New Season of the I am BIO Podcast Explores

February 28, 2023
Media Contact
Theresa Brady
202.962.9235

Spring 2023 Season Takes a Deep Dive Into
Pain Therapies, Artificial Intelligence, FDA’s Accelerated Approvals, and Misinformation

 

Today, the Biotechnology Innovation Organization (BIO) premieres its new I am BIO podcast season, which tells powerful stories of biotech breakthroughs, the people they help, and the global problems they solve.

“We want the American public to know they can trust science and biotechnology innovations, which are improving and saving lives,” said BIO’s CEO Rachel King. “By sharing our industry’s unique approaches to helping solve some of the world’s most pressing problems, we’re arming our listeners with first-hand insight into the exciting world of biotechnology.”

The season launches with a topic that impacts50 million people in the United States daily –chronic pain–and explores safe and effective treatments and how government policies could hinder new treatment developments.

Each year the podcast releases 12 episodes – six in the spring and six beginning in September. The first half of the season will culminate with an episode on science and health misinformation.

Additional episodes during the spring season will cover:

  • The convergence of artificial intelligence and biotechnology
  • Biotech innovation with CRISPR technology
  • Threats to FDA’s Accelerated Approval program

In 2022, PR Daily named the I AM BIO podcast a finalist for its Social Media & Digital Awards in the podcast category. Listen now on BIO’s website, Apple Podcasts, Google Podcasts, or Spotify.

Discover More
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…